Overview

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Status:
RECRUITING
Trial end date:
2025-08-10
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the safety and efficacy of the prophylactic use of Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis and treatment strategy in this population.
Phase:
PHASE2
Details
Lead Sponsor:
Taixing People's Hospital
Treatments:
trilaciclib